ND: |
ME11409130 |
PMID: |
11409130 |
LR: |
20061115 |
CED: |
20010618 |
DCO: |
20011204 |
Autoren: |
Thie NM; Prasad NG; Major PW |
Titel: |
Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: a randomized double blind controlled 3 month clinical trial. |
Quelle: |
The Journal of rheumatology; VOL: 28 (6); p. 1347-55 /200106/ |
PM: |
Print |
SU: |
IM |
Sprache: |
English |
CY: |
Canada |
JID: |
7501984 |
ISSN: |
0315-162X |
CO: |
JRHUA9 |
Institution: |
Orofacial Pain Clinic, Department of Dentistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada. |
DT: |
Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Schlagwörter |
CT: |
ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/*administration & dosage; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/adverse effects; DOUBLE-BLIND METHOD; FEMALE; GLUCOSAMINE/*administration & dosage; GLUCOSAMINE/adverse effects; HUMANS; IBUPROFEN/*administration & dosage; IBUPROFEN/adverse effects; MALE; MIDDLE AGED; OSTEOARTHRITIS/*drug therapy; PAIN/drug therapy; TEMPOROMANDIBULAR JOINT/*; TREATMENT OUTCOME |
CTG: |
ERWACHSENER; ANTIPHLOGISTIKA, NICHTSTEROIDALE/*Verabreichung & Dosierung; ANTIPHLOGISTIKA, NICHTSTEROIDALE/unerwünschte Nebenwirkungen; DOPPELBLINDMETHODE; WEIBLICH; GLUCOSAMIN/*Verabreichung & Dosierung; GLUCOSAMIN/unerwünschte Nebenwirkungen; MENSCH; IBUPROFEN/*Verabreichung & Dosierung; IBUPROFEN/unerwünschte Nebenwirkungen; MÄNNLICH; MENSCHEN IM MITTLEREN LEBENSALTER; OSTEOARTHROSE/*Arzneimitteltherapie; SCHMERZEN/Arzneimitteltherapie; TEMPOROMANDIBULARGELENK/*; BEHANDLUNGSERGEBNIS |
TE: |
Anti-Inflammatory Agents, Non-Steroidal; Ibuprofen/15687-27-1; Glucosamine/3416-24-8 |
CR: |
15687-27-1; 3416-24-8 |
AB: |
OBJECTIVE: To compare the treatment potential of glucosamine sulfate (GS) and ibuprofen in patients diagnosed with temporomandibular joint (TMJ) osteoarthritis (OA). METHODS: Forty women and 5 men received either GS (500 mg tid) or ibuprofen (400 mg tid) for 90 days in a randomized double blind study. Assessment: TMJ pain with function, pain-free, and voluntary maximum mouth opening, Brief Pain Inventory (BPI) questionnaire and masticatory muscle tenderness were performed after a one week washout and at Day 90. Acetaminophen (500 mg) dispensed for breakthrough pain was counted every 30 days to Day 120. RESULTS: In total, 176 adults were interviewed, 45 (26%) qualified, 39 (87%) completed the study (21 GS, 18 ibuprofen). Four discontinued due to stomach upset (3 ibuprofen, one GS), one due to dizziness (GS), one due to inadequate pain control (ibuprofen). Within-group analysis revealed significant improvement compared to baseline of all variables in both treatment groups but no change in acetaminophen used. Fifteen GS (71%) and 11 ibuprofen (61%) improved, with positive clinical response taken as a 20% decrease in primary outcome (TMJ pain with function). The number of patients with positive clinical response was not statistically different between groups (p = 0.73). Between-group comparison revealed that patients taking GS had a significantly greater decrease in TMJ pain with function, effect of pain, and acetaminophen used between Day 90 and 120 compared with patients taking ibuprofen. CONCLUSION: GS and ibuprofen reduce pain levels in patients with TMJ degenerative joint disease. In the subgroup that met the initial efficacy criteria, GS had a significantly greater influence in reducing pain produced during function and effect of pain with daily activities. GS has a carryover effect. |